⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

December 31, 2011European Respiratory JournalOpen Access

Intermittent hypoxia enhances cancer progression in a mouse model of sleep apnoea

Isaac Almendros Josep M. Montserrat José Ramírez Marta Torres Joaquín Durán‐Cantolla Daniel Navajas Ramón Farré

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Intermittent hypoxia enhances cancer

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Almendros et al. (2011) studied this question.

synapsesocial.com/papers/6a9472e1bba503d12d31b06c https://doi.org/10.1183/09031936.00185110

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A3 Adenosine Receptor Activation in Melanoma CellsOriginal Research · 2003 · 100 citations
2Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic disseminationOriginal Research · 2010 · 174 citations
3Pivotal Advance: Eosinophil infiltration of solid tumors is an early and persistent inflammatory host responseOriginal Research · 2006 · 176 citations
4Chronic systemic hypoxia promotes LNCaP prostate cancer growth in vivoOriginal Research · 2010 · 32 citations
5In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivoIn Vitro Study · 2005 · 80 citations

More related papers

Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours2008
The Role of Hypoxia-Induced Factors in Tumor Progression2004
Tumor necrosis is associated with increased alphavbeta3integrin expression and poor prognosis in nodular cutaneous melanomas2008

More from European Respiratory Journal

Single-cell multi-omics in IPF and COPD: from atlas to impactThu,
A phase 2a study with SPL84: A novel RNA-targeted approach to restore CFTR function in people with CF carrying the 3849+10 kb C→T mutationThu,